CN1491104A - 新型改进释放制剂 - Google Patents

新型改进释放制剂 Download PDF

Info

Publication number
CN1491104A
CN1491104A CNA028049144A CN02804914A CN1491104A CN 1491104 A CN1491104 A CN 1491104A CN A028049144 A CNA028049144 A CN A028049144A CN 02804914 A CN02804914 A CN 02804914A CN 1491104 A CN1491104 A CN 1491104A
Authority
CN
China
Prior art keywords
pyridine
methanamide
dimethyl
imidazo
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028049144A
Other languages
English (en)
Chinese (zh)
Inventor
A
A·尤波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0100478A external-priority patent/SE0100478D0/xx
Priority claimed from SE0100477A external-priority patent/SE0100477D0/xx
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1491104A publication Critical patent/CN1491104A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA028049144A 2001-02-13 2002-02-08 新型改进释放制剂 Pending CN1491104A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE01004787 2001-02-13
SE01004779 2001-02-13
SE0100478A SE0100478D0 (sv) 2001-02-13 2001-02-13 Novel formulation
SE0100477A SE0100477D0 (sv) 2001-02-13 2001-02-13 Novel formulation

Publications (1)

Publication Number Publication Date
CN1491104A true CN1491104A (zh) 2004-04-21

Family

ID=26655389

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA028049144A Pending CN1491104A (zh) 2001-02-13 2002-02-08 新型改进释放制剂
CNA028049063A Pending CN1491105A (zh) 2001-02-13 2002-02-08 新的改进释放的制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA028049063A Pending CN1491105A (zh) 2001-02-13 2002-02-08 新的改进释放的制剂

Country Status (18)

Country Link
US (3) US20040067252A1 (https=)
EP (2) EP1368006B1 (https=)
JP (2) JP2004518709A (https=)
KR (1) KR20040058103A (https=)
CN (2) CN1491104A (https=)
AT (1) ATE324871T1 (https=)
AU (1) AU2002228579B2 (https=)
BR (1) BR0206825A (https=)
CA (2) CA2434542A1 (https=)
DE (1) DE60211130T2 (https=)
DK (1) DK1368006T3 (https=)
ES (1) ES2261643T3 (https=)
IL (1) IL157075A0 (https=)
MX (1) MXPA03007092A (https=)
NO (1) NO20033564L (https=)
NZ (2) NZ526993A (https=)
PT (1) PT1368006E (https=)
WO (2) WO2002064118A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117157059A (zh) * 2022-03-30 2023-12-01 贵州生诺生物科技有限公司 X842制剂

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
BR0314804A (pt) * 2002-09-28 2005-08-02 Mcneil Ppc Inc Forma de dosagem de liberação modificada
SE0301904D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab Novel imidazopyridine compound II with therapeutic effect
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0414046A (pt) * 2003-08-29 2006-10-24 Dynogen Pharmaceuticals Inc método de tratamento de um distúrbio de motilidade gastrintestinal, de tratamento de "gerd", de "gerd" noturno, composição farmacêutica, kit que compreende um composto e método para aumentar a motilidade esofágica em um paciente
CN1889931A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾－冻凝方法
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
CA2549225A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
SE0303451D0 (sv) * 2003-12-18 2003-12-18 Astrazeneca Ab New compounds
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2007105016A1 (en) * 2006-03-16 2007-09-20 Euro-Celtique S.A. Pharmaceutical spheroids
CA2753844A1 (en) 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
WO2011000126A1 (zh) * 2009-06-29 2011-01-06 Liu Yu 脂溶性药物组合物、制备方法及其用途
EP2462131B1 (en) 2009-08-07 2014-10-15 American Life Science Pharmaceuticals, Inc. Compositions and methods for treating beta-amyloid related diseases
US20130165880A1 (en) 2010-09-17 2013-06-27 David T. Amos Antimicrobial disposable absorbent articles
US20140037574A1 (en) * 2010-11-26 2014-02-06 Pius Sedowhe Fasinu Pharmaceutical composition
US20130149383A1 (en) * 2011-12-12 2013-06-13 Cory Berkland Sustained release particle formulations of guaifenesin
WO2013090452A1 (en) * 2011-12-12 2013-06-20 Orbis Biosciences, Inc. Sustained release particle formulations
US9867809B2 (en) * 2015-06-30 2018-01-16 Kemin Industries, Inc. Encapsulated active ingredients for controlled enteric release
US9889120B2 (en) 2016-01-14 2018-02-13 Vicus Therapeutics, Llc Combination drug therapies for cancer and methods of making and using them
DE102017108054A1 (de) 2017-04-13 2018-10-18 Natura Werk Gebr. Hiller GmbH & Co. KG Essbare Zusammensetzung zur Verdauungsförderung
AU2021206286A1 (en) 2020-01-10 2024-08-08 Consynance Therapeutics, Inc. Therapeutic combinations of drugs and methods of using them
CN118215738A (zh) 2021-07-22 2024-06-18 加利福尼亚大学董事会 使用纯化的人rna编辑酶的组合物和方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE593354A (https=) * 1959-02-18
NL194389C (nl) * 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4956182A (en) * 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
NZ270439A (en) * 1995-02-02 1996-04-26 Bernard Charles Sherman Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
SE9801526D0 (sv) * 1998-04-29 1998-04-29 Astra Ab New compounds
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117157059A (zh) * 2022-03-30 2023-12-01 贵州生诺生物科技有限公司 X842制剂
CN117157059B (zh) * 2022-03-30 2024-09-13 贵州生诺生物科技有限公司 X842制剂

Also Published As

Publication number Publication date
NO20033564D0 (no) 2003-08-12
DE60211130D1 (de) 2006-06-08
ATE324871T1 (de) 2006-06-15
DK1368006T3 (da) 2006-07-24
EP1368006A1 (en) 2003-12-10
KR20040058103A (ko) 2004-07-03
DE60211130T2 (de) 2006-11-30
JP2004518708A (ja) 2004-06-24
WO2002064121A1 (en) 2002-08-22
CA2434835A1 (en) 2002-08-22
WO2002064118A1 (en) 2002-08-22
US20040067252A1 (en) 2004-04-08
CA2434542A1 (en) 2002-08-22
NZ526994A (en) 2005-01-28
IL157075A0 (en) 2004-02-08
US20080118560A1 (en) 2008-05-22
PT1368006E (pt) 2006-08-31
US20040067256A1 (en) 2004-04-08
EP1368006B1 (en) 2006-05-03
EP1361868A1 (en) 2003-11-19
BR0206825A (pt) 2004-02-25
CN1491105A (zh) 2004-04-21
ES2261643T3 (es) 2006-11-16
NO20033564L (no) 2003-10-02
HK1059740A1 (en) 2004-07-16
MXPA03007092A (es) 2003-11-18
NZ526993A (en) 2005-01-28
JP2004518709A (ja) 2004-06-24
AU2002228579B2 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
CN1491104A (zh) 新型改进释放制剂
CN1189171C (zh) 卡维地洛的亲水分子分散液
CN1213754C (zh) β－咔啉药物组合物
CN1190187C (zh) 差水溶性药物的固态溶液和分散液
CN1298317C (zh) 坦洛新片剂
CN1093758C (zh) 缓释粒状制剂及其制备方法
CN101636152B (zh) 含有西洛他唑的控释制剂及其制备方法
RU2487703C2 (ru) Фармацевтические композиции, включающие модулятор s1р
JP6173521B2 (ja) ナルブフィンを含有する製剤及びそれらの使用
WO2005046696A1 (ja) フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤
CN1607947A (zh) 包含3－(3－二甲基氨基－1－乙基－2－甲基－丙基)苯酚并能提供活性成分的延迟释放的药物
CN1787811A (zh) 口腔崩解片
CN1240132A (zh) 控制释放制剂
KR20110005883A (ko) 침투성이 불량한 활성 약제학적 성분을 위한 개선된 제형
HK1040932B (zh) 攪動非依賴性多元緩釋藥物製劑及其製備方法
CN103596556A (zh) 用于阴道给药的快速溶解片剂组合物
CN1747723A (zh) 含活性成分混合物的组合物及其制备方法
CN1536993A (zh) 包含4-氰基-三氟-n-[3-(4-氟苯磺酰基)-2-羟基-2-甲基丙酰基]-间甲苯胺和pvp的固体药物组合物
JP2013517315A (ja) 新規組成物
CN1509185A (zh) 医药用组合物
US20030190352A1 (en) Compositions of venlafaxine base
CN1842331A (zh) 含有氨磺必利的新颖固体药物组合物
CN1272785A (zh) 微渗透药物控释系统
JP2004525887A (ja) 新規フェノフィブラート錠剤
KR20070116607A (ko) Ｏ-데스메틸벤라팍신 및 바제독시펜의 조합 산물 및 이의용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication